× 10−7)rs452368911:7950797G/AOR10A6IntergenicSI0.27−0.012 (0.003)7.77 × 10−9 (0.00030/2.2 × 10−5)rs93300613:38350193A/GTRPC4IntronicSI0.32−0.0143 (0.003)3.50 × 10−8 (0.022/9.6 × 10−8)rs55789915:47643795A/CSEMA6DIntronicSI0.260.0157 (0.003)2.99 × 10−13 (4.46 × 10−5/1.0 × 10−8)rs7660858219:4474725A/CHDGFRP2IntronicSI0.029−0.0360 (0.007)8.50 × 10−9 (0.012/4.3 × 10−8)Chromosome (Chr) and position (Pos) for each SNV is given for hg19 build 37. Only SNVs reaching genome-wide significance (P < 5 × 10-8, in bold) in the combined meta-analysis are shown. Magnitude of the effect size estimates are not presented as traits were transformed in differently by the three consortia analysed. SNVs identified in the discovery stage of this study (see Table 1) are denoted #. The discovery sample size for smoking initiation (SI), CPD, pack-years (PY), and smoking cessation (SC) were 346,813, 128,746, 131,892, and 121,543, respectively; and the replication sample size for SI, CPD, PY, and SC were 275,596, 80,015, 78,897, and 123,851, respectively. NB: rs6673752 (intronic to UBAP2L) was not available in the discovery cohorts. EA effect allele, OA other allele, Beta(se) beta and standard error for association in the replication stage. All SNVs had heterogeneity P > 0.0001Bold font highlights the genome-wide significant P-values from the meta-analysis of discovery plus replication studiesTable 3Results from conditional analyses at previously reported smoking behaviour lociGene regiondbSNP IDChr:PosEA/OAConsequenceTraitEAFP (unconditional)SNV(s) conditioned onDiscovery Conditional
